BR112013000512A2 - método para produzir uma composição de adamts 13 (ra13) recombinante, sobrenadante de cultura de célula, e , composição adamts13 recombinante (ra13)' - Google Patents

método para produzir uma composição de adamts 13 (ra13) recombinante, sobrenadante de cultura de célula, e , composição adamts13 recombinante (ra13)'

Info

Publication number
BR112013000512A2
BR112013000512A2 BR112013000512A BR112013000512A BR112013000512A2 BR 112013000512 A2 BR112013000512 A2 BR 112013000512A2 BR 112013000512 A BR112013000512 A BR 112013000512A BR 112013000512 A BR112013000512 A BR 112013000512A BR 112013000512 A2 BR112013000512 A2 BR 112013000512A2
Authority
BR
Brazil
Prior art keywords
cell culture
composition
recombinant
culture supernatant
adamts13
Prior art date
Application number
BR112013000512A
Other languages
English (en)
Inventor
Daniel Fleischanderl
Gregor Bramberger
Leopold Grillberger
Manfred Reiter
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013000512(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of BR112013000512A2 publication Critical patent/BR112013000512A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Abstract

método para produzir uma composição de adamts 13 (ra13) recombinante, sobrenadante de cultura de célula, e , composição adamts13 recombinante (ra13). entre outros aspectos, a presente invenção se relaciona com condições de cultura celular para a produção de vwf de alto peso molecular, em particular, wf altamente multimérico com uma alta atividade específica e adamts13 com uma allta atividade específica. as condições de cultura celular de presente invenção podem incluir, por exemp´lo, um meio de cultura celular com uma maior concentração de cobre e/ou sobrenadante de cultura de célula com uma concentração baixa de amônio (nh4). a presente invenção também fornece métodos para cultivar células nas condições de cultura de células para expressar vwf de alto peso molecular e ra13 tendo atividades específicas altas.
BR112013000512A 2010-07-08 2011-07-08 método para produzir uma composição de adamts 13 (ra13) recombinante, sobrenadante de cultura de célula, e , composição adamts13 recombinante (ra13)' BR112013000512A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36263510P 2010-07-08 2010-07-08
PCT/US2011/043459 WO2012006594A1 (en) 2010-07-08 2011-07-08 Method of producing recombinant adamts13 in cell culture

Publications (1)

Publication Number Publication Date
BR112013000512A2 true BR112013000512A2 (pt) 2016-05-17

Family

ID=44514323

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013000512A BR112013000512A2 (pt) 2010-07-08 2011-07-08 método para produzir uma composição de adamts 13 (ra13) recombinante, sobrenadante de cultura de célula, e , composição adamts13 recombinante (ra13)'
BR112013000515-7A BR112013000515B1 (pt) 2010-07-08 2011-07-08 Método para produzir uma composição de fator von willebrand recombinante (rvwf)

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112013000515-7A BR112013000515B1 (pt) 2010-07-08 2011-07-08 Método para produzir uma composição de fator von willebrand recombinante (rvwf)

Country Status (25)

Country Link
US (8) US9458222B2 (pt)
EP (6) EP2591094B1 (pt)
JP (3) JP6138683B2 (pt)
KR (4) KR101894604B1 (pt)
CN (4) CN107286235A (pt)
AU (6) AU2011274470B2 (pt)
BR (2) BR112013000512A2 (pt)
CA (2) CA2804275A1 (pt)
CO (2) CO6690745A2 (pt)
DK (3) DK2590998T3 (pt)
EA (5) EA029503B1 (pt)
ES (4) ES2761692T5 (pt)
FI (1) FI3064508T4 (pt)
HR (3) HRP20192089T4 (pt)
HU (3) HUE038193T2 (pt)
IL (5) IL286298B (pt)
MX (3) MX2013000166A (pt)
NZ (2) NZ605404A (pt)
PL (4) PL2591094T3 (pt)
PT (3) PT2591094T (pt)
SG (3) SG10201809632XA (pt)
SI (3) SI3064508T2 (pt)
TR (1) TR201815211T4 (pt)
TW (4) TWI670073B (pt)
WO (2) WO2012006594A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2745805C (en) * 2008-12-05 2021-01-19 Baxter International Inc. Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
BR112013000512A2 (pt) 2010-07-08 2016-05-17 Baxter Healthcare Sa método para produzir uma composição de adamts 13 (ra13) recombinante, sobrenadante de cultura de célula, e , composição adamts13 recombinante (ra13)'
ES2682249T3 (es) 2011-06-10 2018-09-19 Baxalta GmbH Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante
US9030963B2 (en) * 2012-12-03 2015-05-12 Honeywell International Inc. Analyzing a network topology
UY35343A (es) * 2013-02-26 2014-09-30 Bayer Healthcare Llc Formulaciones y procedimientos para la producción de proteína recombinante aumentada
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
US10544231B2 (en) 2014-04-16 2020-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
EP3158055B1 (en) * 2014-06-13 2019-09-11 CSL Limited Improved production of recombinant von willebrand factor in a bioreactor
MA41685A (fr) * 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
KR102638596B1 (ko) * 2015-02-05 2024-02-21 알.피.쉐러 테크놀러지즈 엘엘씨 활성화된 포르밀글리신-생성 효소 및 그것의 생산 및 사용 방법
AR104050A1 (es) * 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
AU2017307582C1 (en) 2016-08-04 2021-05-06 Takeda Pharmaceutical Company Limited Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
CN106957815B (zh) * 2017-03-16 2021-05-07 杨涛 一种用于人类多潜能干细胞的无血清培养基的配方
WO2019010497A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION
EP3648787A1 (en) 2017-07-07 2020-05-13 Baxalta Incorporated Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
BR112020019057A2 (pt) 2018-03-21 2020-12-29 Baxalta Incorporated Método para obter uma composição, e, composição farmacêutica.
EA202192140A1 (ru) 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10961500B1 (en) 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
JP2022547556A (ja) 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
AU2021216945A1 (en) 2020-02-04 2022-09-01 Takeda Pharmaceutical Company Limited Treatment of menorrhagia in patients with severe von Willebrand Disease by administration of recombinant VWF
WO2021234458A1 (en) 2020-05-22 2021-11-25 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
NL8500961A (nl) 1985-04-01 1986-11-03 Stichting Vrienden Van De Stic Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten.
AU591671B2 (en) 1985-04-11 1989-12-14 Children's Medical Center Corporation Von willebrand factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
EP1213030B1 (en) 1994-11-10 2009-04-22 Baxter Healthcare SA Method for producing biologicals in protein-free culture
CA2211630A1 (en) 1995-02-23 1996-08-29 Quest International B.V. Peptides for tissue and cell culture media
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2000517188A (ja) 1996-08-30 2000-12-26 ライフ テクノロジーズ，インコーポレイテッド 無血清哺乳動物細胞培養培地およびその使用
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
ATE399855T1 (de) 1996-10-10 2008-07-15 Invitrogen Corp Tierzellkulturmedium mit pflanzlichen nährstoffen
US6156570A (en) * 1997-03-20 2000-12-05 Regents Of The University Of Minnesota Process for the continuous culture of cells
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
JP2001120262A (ja) 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
CN1596302A (zh) * 2001-11-28 2005-03-16 桑多斯有限公司 细胞培养方法
JP2005532033A (ja) 2002-01-17 2005-10-27 ロンザ・バイオロジクス・ピーエルシー タンパク質を産生する能力を有し且つ無グルタミン培地中で成長する能力を有するグルタミン栄養要求性ヒト細胞
US20050084828A1 (en) 2003-10-21 2005-04-21 The University Of North Carolina At Chapel Hill Apparatus and method for braille instruction
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US8273553B2 (en) * 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
EP1807504B1 (en) * 2004-11-02 2011-02-23 Ares Trading S.A. Serum-free cell culture medium for mammalian cells
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US20070212770A1 (en) 2006-01-04 2007-09-13 Baxter International Inc. Oligopeptide-free cell culture media
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CN101490239A (zh) * 2006-07-14 2009-07-22 帝斯曼知识产权资产管理有限公司 改进的细胞培养方法
TW201516149A (zh) * 2006-09-13 2015-05-01 Abbvie Inc 細胞培養改良
US7960869B2 (en) 2006-09-22 2011-06-14 Siemens Industry, Inc. Internal intelligence for remote operated relay
JP5702066B2 (ja) * 2006-12-27 2015-04-15 ネクター セラピューティクス 解離可能な連結を有するフォンウィルブランド因子および第ｖｉｉｉ因子のポリマー共役体
EP2115126B1 (en) * 2007-03-02 2015-04-08 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
DE102007046611A1 (de) * 2007-09-28 2009-04-02 Osram Opto Semiconductors Gmbh Lichtquelle mit Konversionselement und Lichtwellenleiter, Verfahren zur Herstellung der Lichtquelle und deren Verwendung
SG10201503304RA (en) * 2007-12-27 2015-06-29 Baxter Int Cell culture processes
PT2240578T (pt) 2007-12-31 2019-06-19 Baxalta GmbH Furina recombinante substancialmente isenta de proteínas animais e métodos para a sua produção
JP4458167B2 (ja) * 2008-01-11 2010-04-28 住友金属工業株式会社 熱間塑性加工用潤滑剤を用いる継目無管製造における外面潤滑方法
WO2009116044A2 (en) 2008-03-19 2009-09-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compounds for treating bacterial infections
DK2310523T3 (en) * 2008-04-17 2015-07-20 Wyeth Llc Methods for increasing the production of bone morphogenetic proteins
US8486699B2 (en) 2008-05-23 2013-07-16 The United States Of America As Represented By The Secretary Of Agriculture Immortal unipotent porcine PICM-19H and PICM-19B stem cell lines
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
KR101574056B1 (ko) * 2009-07-31 2015-12-02 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
BR112013000512A2 (pt) 2010-07-08 2016-05-17 Baxter Healthcare Sa método para produzir uma composição de adamts 13 (ra13) recombinante, sobrenadante de cultura de célula, e , composição adamts13 recombinante (ra13)'
TWI408228B (zh) 2010-10-29 2013-09-11 Univ Nat Chunghsing 用於生產一標的蛋白質的核酸建構物、重組型載體以及方法

Also Published As

Publication number Publication date
US20190085052A1 (en) 2019-03-21
JP2013533748A (ja) 2013-08-29
EA035066B1 (ru) 2020-04-23
JP2017217004A (ja) 2017-12-14
AU2022200035A1 (en) 2022-01-20
JP6138683B2 (ja) 2017-05-31
ES2761692T3 (es) 2020-05-20
EP2591094B1 (en) 2018-09-05
KR20130091328A (ko) 2013-08-16
SG186935A1 (en) 2013-02-28
KR101894604B1 (ko) 2018-09-03
EA201792340A3 (ru) 2018-07-31
TR201815211T4 (tr) 2018-11-21
MX339632B (es) 2016-06-02
EP3392271B1 (en) 2021-05-05
EA201792340A2 (ru) 2018-02-28
US9458222B2 (en) 2016-10-04
HRP20192089T4 (hr) 2023-04-28
DK3064508T4 (da) 2023-04-11
AU2011274467A1 (en) 2013-01-24
KR20180099922A (ko) 2018-09-05
IL286298A (en) 2021-10-31
IL255327B (en) 2020-04-30
SI2590998T1 (en) 2018-06-29
WO2012006594A1 (en) 2012-01-12
PL3064508T3 (pl) 2020-02-28
MX353409B (es) 2018-01-11
HRP20180136T1 (hr) 2018-04-06
IL273304B (en) 2021-09-30
EP2590998A1 (en) 2013-05-15
SI3064508T2 (sl) 2023-05-31
AU2018200206A1 (en) 2018-04-05
AU2020203565B2 (en) 2021-09-30
MX2013000166A (es) 2013-06-05
EA202090067A2 (ru) 2020-04-30
EP3064508B2 (en) 2023-03-15
CN103097409A (zh) 2013-05-08
US11780904B2 (en) 2023-10-10
FI3064508T4 (fi) 2023-04-25
CN108060154A (zh) 2018-05-22
SG186936A1 (en) 2013-02-28
PL3064508T5 (pl) 2024-04-08
KR102007773B1 (ko) 2019-08-06
EP3626736A1 (en) 2020-03-25
EA201390080A1 (ru) 2013-06-28
US20150056657A1 (en) 2015-02-26
US20180044405A1 (en) 2018-02-15
KR20130091329A (ko) 2013-08-16
US9409971B2 (en) 2016-08-09
US10822394B2 (en) 2020-11-03
HRP20192089T1 (hr) 2020-03-20
AU2015207811A1 (en) 2015-08-20
CO6690745A2 (es) 2013-06-17
EP2591094A1 (en) 2013-05-15
PL3392271T3 (pl) 2021-11-15
EA202090220A3 (ru) 2020-08-31
HUE046443T2 (hu) 2020-03-30
MX2013000165A (es) 2013-06-05
PT2590998T (pt) 2018-02-13
IL223930A (en) 2017-01-31
NZ605404A (en) 2014-08-29
CA2804275A1 (en) 2012-01-12
EP3392271A1 (en) 2018-10-24
CA2805557A1 (en) 2012-01-12
IL286298B (en) 2022-08-01
IL255327A0 (en) 2017-12-31
JP2013538046A (ja) 2013-10-10
DK3064508T3 (da) 2019-11-25
EA201390082A1 (ru) 2013-06-28
WO2012006591A1 (en) 2012-01-12
AU2011274470A1 (en) 2013-01-24
AU2015207811B2 (en) 2017-10-19
EA035147B1 (ru) 2020-05-06
AU2011274470B2 (en) 2015-08-13
DK2591094T3 (en) 2018-11-26
PL2591094T3 (pl) 2019-02-28
ES2761692T5 (es) 2023-07-05
JP6284919B2 (ja) 2018-02-28
EP3064508B1 (en) 2019-08-28
TW201900207A (zh) 2019-01-01
EA202090220A2 (ru) 2020-05-31
ES2875772T3 (es) 2021-11-11
TWI670073B (zh) 2019-09-01
US20120035110A1 (en) 2012-02-09
PT3064508T (pt) 2019-12-05
EA202090067A3 (ru) 2020-07-31
AU2018200206B2 (en) 2020-05-28
US9834591B2 (en) 2017-12-05
HRP20181657T1 (hr) 2019-03-08
AU2011274467B2 (en) 2015-01-15
SI3064508T1 (sl) 2019-12-31
SI2591094T1 (sl) 2018-12-31
EP3909977A1 (en) 2021-11-17
DK2590998T3 (en) 2018-02-12
CN103097522A (zh) 2013-05-08
EP3064508A1 (en) 2016-09-07
TWI609890B (zh) 2018-01-01
AU2020203565A1 (en) 2020-06-18
TWI617575B (zh) 2018-03-11
US10100099B2 (en) 2018-10-16
KR101924120B1 (ko) 2018-11-30
NZ605403A (en) 2014-10-31
CO6680636A2 (es) 2013-05-31
ES2664392T3 (es) 2018-04-19
SG10201809632XA (en) 2018-12-28
JP5953502B2 (ja) 2016-07-20
EP3392271B8 (en) 2021-06-16
ES2694518T3 (es) 2018-12-21
KR102027991B1 (ko) 2019-10-02
TW201206953A (en) 2012-02-16
EA029503B1 (ru) 2018-04-30
CN107286235A (zh) 2017-10-24
PL2590998T3 (pl) 2018-05-30
US20170008948A1 (en) 2017-01-12
TWI646972B (zh) 2019-01-11
KR20180130587A (ko) 2018-12-07
BR112013000515A2 (pt) 2016-05-17
EP2590998B1 (en) 2017-11-15
JP2016025873A (ja) 2016-02-12
IL223929A (en) 2017-11-30
BR112013000515B1 (pt) 2021-11-03
HUE11738351T2 (hu) 2019-03-28
US20150018525A1 (en) 2015-01-15
HUE038193T2 (hu) 2018-09-28
PT2591094T (pt) 2018-11-20
TW201204744A (en) 2012-02-01
US8852888B2 (en) 2014-10-07
IL273304A (en) 2020-04-30
US20210115110A1 (en) 2021-04-22
US20120034674A1 (en) 2012-02-09
TW201637665A (zh) 2016-11-01

Similar Documents

Publication Publication Date Title
BR112013000512A2 (pt) método para produzir uma composição de adamts 13 (ra13) recombinante, sobrenadante de cultura de célula, e , composição adamts13 recombinante (ra13)'
BRPI0514694A (pt) produção de proteìna de fusão tnfr-ig
EA201270224A1 (ru) Среда для культивирования клеток для экспрессии белков adamts
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
WO2009002456A3 (en) Methods and compositions relating to progenitor cells
DE60031419D1 (de) Zusammensetzungen und verfahren für verbesserte zellkultur
SG10201901417UA (en) Production of proteins in glutamine-free cell culture media
AU2009209251A8 (en) Stabilized Angiopoietin-2 antibodies and uses thereof
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
WO2010096588A3 (en) Cell culture media containing combinations of proteins
MY156588A (en) Systems using cell culture for production of isoprene
WO2011091350A3 (en) Methods & compositions for improving protein production
BRPI0514703A (pt) produção de polipeptìdeos
BRPI0516572A (pt) métodos e composições para melhorar a produção de proteìnas recombinantes
WO2011075686A3 (en) Methods & compositions comprising heat shock proteins
AR069956A1 (es) Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas
WO2006017134A3 (en) Preprimitive streak and mesendoderm cells
TR201900213T4 (tr) Bir sürekli hücre kültüründe bir polipeptit veya ilişkin virüsün üretim metodu.
EP2588594A4 (en) METHODS FOR CULTURING INDIFFERENCED CELLS USING EXTENDED RELEASE COMPOSITIONS
EA201400877A1 (ru) Микроорганизмы, ферментирующие пентозы
WO2012028945A3 (en) Mutants of l-asparagine
MX2015010887A (es) Formulaciones y metodos para aumentar la produccion de proteinas recombinantes.
BRPI0518449A2 (pt) mÉtodos para produzir cÉlulas mamÍferas
WO2010027789A3 (en) Volume exclusion agent to enhance formation of extracelluar matrix
BR112014020747A2 (pt) método para a redução de 1->2 deslocamentos de estruturas de leitura

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: BAXTER INTERNATIONAL INC (US) , BAXTER HEALTHCARE

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAXALTA INCORPORATED (US) , BAXALTA GMBH (CH)

B15G Petition not considered as such [chapter 15.7 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)